Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-07-26
2011-07-26
Blanchard, David J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S009100, C424S133100, C424S141100, C424S143100, C424S155100, C424S178100, C424S181100, C424S183100, C435S069600, C435S070210, C530S388100, C530S388220, C530S388800, C530S391700
Reexamination Certificate
active
07985842
ABSTRACT:
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.
REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 5686583 (1997-11-01), Bosslet et al.
patent: 6315997 (2001-11-01), do Couto et al.
patent: 2003/0099655 (2003-05-01), Watkins et al.
patent: 2003/0165502 (2003-09-01), Fujita-Yamaguchi
patent: 2003/0195147 (2003-10-01), Pillutla et al.
patent: 2003/0236190 (2003-12-01), Pillutla et al.
patent: 2004/0023887 (2004-02-01), Pillutla et al.
patent: 2004/0086503 (2004-05-01), Cohen et al.
patent: 97/21732 (1997-06-01), None
patent: 00/34780 (2000-06-01), None
patent: 01/83806 (2001-11-01), None
patent: 02/053596 (2002-07-01), None
patent: 03/059951 (2003-07-01), None
patent: 03/100008 (2003-12-01), None
patent: 03/106621 (2003-12-01), None
patent: 2004/071529 (2004-08-01), None
patent: 2004/083248 (2004-09-01), None
Bendig M. M. Methods: A Companion to Methods in Enzymology, 8:83-93, 1995.
MacCallum et al. J. Mol. Biol., 262, 732-745, 1996.
Casset et al. Biochemical and Biophysical Research Communications, 307:198-205, 2003.
Alberts et al. Molecular Biology of the Cell, 3rd ed, pp. 1216-1218, 1994.
Partial English translation of Russian Office Action dated Aug. 21, 2009 in corresponding Russian Patent Application No. 2004136981.
Soos et al., “A Panel of Monoclonal Antibodies for the Type I Insulin-like Growth Factor Receptor, Epitope Mapping, Effects on Ligand Binding, and Biological Activity”, The Journal of Biological Chemistry, 267: 12955-12963, 1992.
Cullen et al., “Insulin-like Growth Factor Receptor Expression and Function in Human Breast Cancer”, Cancer Research, 50:48-53, 1990.
Paul, Fundamental Immunology, 3rd Edition, pp. 292-295 (1993).
Coleman, Research in Immunology, 145:33-36 (1994).
Grant et al, J. Clinical Endocrinology and Metabolism, 83:3252-3257 (1998).
Steele-Perkins et al, Biochem. Biophys. Res. Comm., 171(3):1244-1251 (1990).
Kato et al, J. Biol. Chem., 268:2655-2661 (1993).
Harlow and Lane, eds. Using Antibodies, A Laboratory Manual, pp. 81-97, 126-127, 166-169, Cold Spring Harbor Press (1999).
Paul, Fundamental Immunology, 3rd Edition, pp. 242 (1993).
Rudikoff et al, Proc. Natl. Acad. Sci. USA, 79:1979-1983 (1982).
Zia et al, Journal of Cellular Biochemistry Supplement, 24:269-275 (1996).
Roguska et al., Proc. Natl. Acad. Sci., USA, 91:969-973 (1994).
Li et al, Cancer Immunol. Immunother., 49:243-252 (2000).
Maloney et al., Cancer Research, 63(16):5073-5083 (2003).
Surmacz, “Growth Factor Receptors as Therapeutic Targets: Strategies to Inhibit the Insulin-like Growth Factor I Receiptor”,Oncogene, Nature Publishing Group, GB Basingstoke, Hants; 22(42):6589-6597 (2003).
NCBI Blast: Protein Sequence (113 Letters), Ig kappa chain (monoclonal antibody MabA34)—mouse (fragment); Accession No. PC4203, dated Dec. 31, 1996 (search Aug. 20, 2009), as search in Russian Patent Application No. 2004/1369841, Partial English Translation of Russian Office Action dated Aug. 21, 2009, in corresponding Russian Patent Application No. 20041369841.
Dagdigian Nancy E.
Singh Rajeeva
Tavares Daniel J.
Blanchard David J.
Immunogen Inc.
Sughrue & Mion, PLLC
LandOfFree
Anti-IGF-I receptor antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-IGF-I receptor antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-IGF-I receptor antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2663499